Patient advocacy

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

Retrieved on: 
Wednesday, February 28, 2024
SAN, Woman, Caregiver, Education, Cardiovascular disease, Engagement, Empowerment, Activate, Patient advocacy, Hypertrophic cardiomyopathy, Navigation, HCM, Patient, Clinical trial, Health equity, Mended Hearts, Cytokinetics, Nursing

ENACT is a joint initiative of The Mended Hearts, Inc. and WomenHeart, made possible through grant funding from Cytokinetics provided to each organization to address their respective constituencies.

Key Points: 
  • ENACT is a joint initiative of The Mended Hearts, Inc. and WomenHeart, made possible through grant funding from Cytokinetics provided to each organization to address their respective constituencies.
  • The goal of ENACT is to provide greater education to patients with cardiovascular diseases participating in clinical trials.
  • During the initial launch, The Mended Hearts, Inc. and WomenHeart will create complementary content, modules and resources based on their unique expertise and constituencies.
  • “We commend The Mended Hearts, Inc. and WomenHeart on this joint initiative to help make cardiovascular clinical trials more accessible, approachable and inclusive,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Advocacy and Engagement.

Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program

Retrieved on: 
Monday, January 29, 2024
Woman, ALS Therapy Development Institute, Patient, Heart, GHH, ALS, SAN, ALS TDI, Science, Cardiomyopathy, Patient advocacy, Heart failure, Engagement, HCM, Hypertrophic cardiomyopathy, Caregiver, Cytokinetics, Cardiovascular disease, Heart transplantation, Human, Organization, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement.
  • The grants will support projects to increase access to resources, grow organizational reach and launch educational programs.
  • Cardiomyopathy UK will use the grant to expand Reaching Further, a project aimed at educating those not diagnosed with cardiomyopathy about the symptoms and warning signs.
  • The grant will allow Cardiomyopathy UK to create 15 additional case study stories and refine and optimize the organization’s website.

Amy Dixon, Blind Paralympian, Joins eyecbetter as Director of Patient Advocacy

Retrieved on: 
Wednesday, October 18, 2023
Sport, Glaucoma, Life, Patient advocacy, Athlete, Paralympic Games, Eye, Paratriathlon, Autoimmune disease, Disability, CMO, Patient, Nursing

Decorated blind Paralympian, Amy Dixon joins eyecbetter as Director of Patient Advocacy, because life is worth seeing.

Key Points: 
  • Decorated blind Paralympian, Amy Dixon joins eyecbetter as Director of Patient Advocacy, because life is worth seeing.
  • As Director of Patient Advocacy, Ms. Dixon will play a critical role in furthering eyecbetter's mission of improving patient outcomes through wearable health technology and remote patient monitoring.
  • "We are honored to welcome Amy Dixon as our Director of Patient Advocacy," said Joy Glen, CMO of eyecbetter.
  • Please join us in welcoming Amy Dixon to the eyecbetter team and acknowledging her valuable contributions as Director of Patient Advocacy.

Obesity Control Center Reaffirms Commitment to Quality Care Through Latest GHA Accreditation

Retrieved on: 
Tuesday, October 10, 2023
BEACH, Government, Education, Control center, Accreditation, Communication, Anesthesiology, Medical tourism, GHA, Patient advocacy, Safety, Travel, Interim, International, Trust, Patient safety, Nursing, Cultural competence, Bariatric surgery, PALM, Exercise, English, Risk management, Patient, Chronic care management, Hospital, Medical device

PALM BEACH GARDENS, Fla., Oct. 10, 2023 /PRNewswire/ -- Obesity Control Center has been awarded Accreditation for Medical Travel Services by Global Healthcare Accreditation (GHA) for a second term, underscoring its commitment to exceptional care for traveling patients.

Key Points: 
  • PALM BEACH GARDENS, Fla., Oct. 10, 2023 /PRNewswire/ -- Obesity Control Center has been awarded Accreditation for Medical Travel Services by Global Healthcare Accreditation (GHA) for a second term, underscoring its commitment to exceptional care for traveling patients.
  • Obesity Control Center was first accredited by GHA, the global leader in medical travel accreditation, in 2019.
  • "We congratulate Obesity Control Center on attaining GHA Accreditation for a second term and for their dedication to excellence in medical travel," said Ms. Renée-Marie Stephano, Interim Chief Executive Officer of Global Healthcare Accreditation."
  • With Obesity Control Center renewing its GHA Accreditation, the organization continues as an esteemed member of GHA's internationally recognized provider network .

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

Retrieved on: 
Thursday, September 28, 2023
Communication, Application, Patient advocacy, Heart failure, Criterion, Cardiovascular disease, National Coalition of Syrian Revolutionary and Opposition Forces, Organization, Mended Hearts, Cytokinetics, Hypertrophic cardiomyopathy, Woman, ALS, HCM, Engagement, Pharmaceutical industry, Nursing

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the sixth annual Cytokinetics Communications Grant Program. The program will award five grants in the amount of $20,000 each to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM), heart failure and amyotrophic lateral sclerosis (ALS) communities. The grants are intended to support increased capacity in communications, awareness building and community engagement.

Key Points: 
  • Deadline for Applications is November 1st, 2023
    SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the sixth annual Cytokinetics Communications Grant Program.
  • “Over the past five years, our Communications Grant Program has funded creative and urgently needed programs that have helped expand patient reach, connect communities and elevate patient voices.
  • Funding from the Cytokinetics Communications Grant program may help with communications programming or personnel, depending on each organization’s needs.
  • Applications will be evaluated by a committee of representatives from Cytokinetics based on the proposal’s alignment with selection criteria.

Travere Therapeutics Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level

Retrieved on: 
Friday, September 8, 2023
American Kidney Fund, Patient advocacy, AKF, Sarah Travers, Research, Patient, Risk, Kidney, Health, Therapy, Kidney disease, Disease, Pharmaceutical industry

ROCKVILLE, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Travere Therapeutics has joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.

Key Points: 
  • ROCKVILLE, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Travere Therapeutics has joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.
  • Travere’s membership will help fund AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research.
  • Recently, Travere supported AKF’s Unknown Causes of Kidney Disease Project , which aims to improve understanding of how undiagnosed or misdiagnosed causes of kidney disease directly impact patient care and outcomes.
  • The Corporate Membership Program is open to institutional partners that support AKF’s mission of fighting kidney disease and helping people live healthier lives.

Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit

Retrieved on: 
Friday, July 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Allergy, Hereditary angioedema, HAE, First Nations Summit, Therapy, Patient advocacy, Pharmaceutical industry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 US Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida from July 20-23, 2023.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 US Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida from July 20-23, 2023.
  • Sarah Friedhoff, Director of Patient Advocacy at Astria Therapeutics, will present “People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as a Target for Therapeutic Efficacy,” in a poster session beginning on Friday, July 21, at 7:45am ET.
  • This poster will be available in-person to registered attendees and will be made available on www.astriatx.com following the conference.

Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Business development, Patient advocacy, Half-life, Corporate communication, Hereditary angioedema, Pharmacokinetics, American Academy, American Academy of Allergy, Asthma, and Immunology, Strategic management, Organization, Asthma, Plasma, HAE, Patient, Investment, Allergy, AAAAI, Research, Therapy, Angioedema, IND, Safety, D, Pharmaceutical industry, Nursing, Cryptocurrency

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • We on track to share initial proof-of-concept results which are anticipated in mid-2024,” said Jill C. Milne, Ph.D., Chief Executive Office at Astria.
  • In the fourth quarter of 2023, the company expects initial Phase 1a results from the additional cohorts in healthy subjects, as well as final results from cohorts 1 through 3.
  • She will be responsible for leading the company’s Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy functions.

Astria Therapeutics Names Andrea Matthews Chief Business Officer

Retrieved on: 
Wednesday, April 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Operation, Corporate Affairs, Business development, Patient advocacy, Senior, Corporate communication, Hereditary angioedema, Boston University, Strategic management, Molecular biology, HAE, Patient, Allergy, Management, Therapy, Massachusetts Institute of Technology, Corporate development, Biochemistry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief Business Officer.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief Business Officer.
  • Ms. Matthews brings 20 years of business experience to the role and has been with the company for close to nine years, most recently as Senior Vice President, Corporate Affairs.
  • “Andrea has made important contributions to significant inflection points over her years at the company,” said Jill C. Milne, Chief Executive Officer at Astria.
  • Prior to joining Astria, Ms. Matthews served as Vice President, Operations and Alliance Management/Commercial Operations at Selventa (formerly Genstruct) from 2010 and Director, Alliance Management from 2009.

EISAI AND PATIENT ADVOCACY PARTNERS LAUNCH MADE OF MORE -- AN EDUCATION INITIATIVE TO SPOTLIGHT HEAD AND NECK CANCER

Retrieved on: 
Tuesday, April 11, 2023
Survivor, Heart, Insurance, Patient advocacy, Life, HNCA, Head, Corporate communication, Head and Neck Cancer Alliance, Cancer, Made, Support, Risk, Eisai, Community, University of California, San Diego, UC, MD, Patient, UC San Diego Health, Fertility, Oral, Diagnosis, Social media, Caregiver, Disease, Dentistry, Nursing

NUTLEY, N.J., April 11, 2023 /PRNewswire/ -- Head and Neck Cancer Alliance (HNCA), Support for People with Oral and Head and Neck Cancer (SPOHNC), Thyroid, Head And Neck Cancer (THANC) Foundation, CancerCare and Eisai Inc. have partnered to launch Made of More, a unique initiative that aims to help individuals impacted by head and neck cancer band together as one community and remind themselves and others that they are made of more than this disease.

Key Points: 
  • Compared to other types of cancer, head and neck cancer receives little public attention and is not well understood.
  • At the heart of this initiative are head and neck cancer survivors and caregivers who share their unique life experiences before, during and after diagnosis.
  • "The journey after a head and neck cancer diagnosis can be complex and often leaves patients feeling afraid and confused.
  • To learn more about Made of More and head and neck cancer, and access useful resources, visit MadeofMore.com .